Pfizer Animal Health and The Hippolia Foundation — a network of leading French equine institutions — have formed a strategic partnership to advance equine health through research and educational programs.
Advancing horse health worldwide
Hippolia will collaborate with Pfizer to advance and accelerate innovation in the diagnosis, treatment and prevention of equine disease.
Hippolia will collaborate with Pfizer to advance and accelerate innovation in the diagnosis, treatment and prevention of equine disease, with a specific focus on respiratory disorders and infectious diseases. Both Hippolia and Pfizer are initially investing more than $5 million in the partnership over the next three years.
"Together, The Hippolia Foundation and Pfizer have created a partnership that will leverage the diagnostic and scientific capabilities of what today is the largest equine research network worldwide," said Alejandro Bernal, Pfizer Animal Health Area President, Europe/Africa/Middle East. "Both parties will benefit from the combined expertise and resources in the interests of accelerating pioneering equine research."
"This is an excellent example of a public/private initiative to advance our scientific knowledge and improve animal health and welfare," said Pierre Lekeux, President, The Hippolia Foundation.
Founded in 2011 and located in Normandy at the center of one of Europe's most recognized regions for competition horses, The Hippolia Foundation supports and promotes the development of research programs, training and services at an international level, particularly on issues of health, welfare and performance in horses.
The Normandy site conducts leading-edge research on racehorses (thoroughbred and standard-bred), as well as on sport horses. The Hippolia Foundation also has existing partnerships with hospitals.